|
nasdaq:cytk
|
14567
|
Apr 21st, 2024 12:00AM
|
Cytokinetics
|
22K
|
475.00
|
Open
|
|
Apr 20th, 2024 11:19PM
|
Apr 20th, 2024 11:19PM
|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
|
Open
|
Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
|
Open
|
350 Oyster Point Blvd
|
South San Francisco
|
California
|
US
|
94080
|
|
Cytokinetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cytk
|
14567
|
Apr 20th, 2024 12:00AM
|
Cytokinetics
|
22K
|
475.00
|
Open
|
|
Apr 19th, 2024 11:16PM
|
Apr 20th, 2024 04:52PM
|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
|
Open
|
Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
|
Open
|
350 Oyster Point Blvd
|
South San Francisco
|
California
|
US
|
94080
|
|
Cytokinetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cytk
|
14567
|
Apr 19th, 2024 12:00AM
|
Cytokinetics
|
22K
|
475.00
|
Open
|
|
Apr 18th, 2024 11:23PM
|
Apr 18th, 2024 11:23PM
|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
|
Open
|
Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
|
Open
|
350 Oyster Point Blvd
|
South San Francisco
|
California
|
US
|
94080
|
|
Cytokinetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cytk
|
14567
|
Apr 18th, 2024 12:00AM
|
Cytokinetics
|
22K
|
475.00
|
Open
|
|
Apr 17th, 2024 11:31PM
|
Apr 18th, 2024 06:12PM
|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
|
Open
|
Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
|
Open
|
350 Oyster Point Blvd
|
South San Francisco
|
California
|
US
|
94080
|
|
Cytokinetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cytk
|
14567
|
Apr 17th, 2024 12:00AM
|
Cytokinetics
|
22K
|
475.00
|
Open
|
|
Apr 16th, 2024 11:13PM
|
Apr 17th, 2024 02:36PM
|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
|
Open
|
Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
|
Open
|
350 Oyster Point Blvd
|
South San Francisco
|
California
|
US
|
94080
|
|
Cytokinetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cytk
|
14567
|
Apr 16th, 2024 12:00AM
|
Cytokinetics
|
22K
|
475.00
|
Open
|
|
Apr 15th, 2024 11:10PM
|
Apr 16th, 2024 10:53AM
|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
|
Open
|
Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
|
Open
|
350 Oyster Point Blvd
|
South San Francisco
|
California
|
US
|
94080
|
|
Cytokinetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cytk
|
14567
|
Apr 15th, 2024 12:00AM
|
Cytokinetics
|
22K
|
475.00
|
Open
|
|
Apr 14th, 2024 11:05PM
|
Apr 15th, 2024 04:34PM
|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
|
Open
|
Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
|
Open
|
350 Oyster Point Blvd
|
South San Francisco
|
California
|
US
|
94080
|
|
Cytokinetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cytk
|
14567
|
Apr 14th, 2024 12:00AM
|
Cytokinetics
|
22K
|
474.00
|
Open
|
|
Apr 13th, 2024 10:54PM
|
Apr 13th, 2024 10:54PM
|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
|
Open
|
Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
|
Open
|
350 Oyster Point Blvd
|
South San Francisco
|
California
|
US
|
94080
|
|
Cytokinetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cytk
|
14567
|
Apr 13th, 2024 12:00AM
|
Cytokinetics
|
22K
|
474.00
|
Open
|
|
Apr 12th, 2024 10:45PM
|
Apr 13th, 2024 11:20AM
|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
|
Open
|
Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
|
Open
|
350 Oyster Point Blvd
|
South San Francisco
|
California
|
US
|
94080
|
|
Cytokinetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cytk
|
14567
|
Apr 12th, 2024 12:00AM
|
Cytokinetics
|
22K
|
474.00
|
Open
|
|
Apr 11th, 2024 10:49PM
|
Apr 12th, 2024 08:15AM
|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
|
Open
|
Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
|
Open
|
350 Oyster Point Blvd
|
South San Francisco
|
California
|
US
|
94080
|
|
Cytokinetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|